Attitudes toward genetic testing for cancer risk after genetic counseling and decision support: A qualitative comparison between hereditary cancer types

Genetic Testing

Volumn 11, Issue 4, 2007, Pages 401-411

  Wakefield, Claire E ^a,b,c   Kasparian, Nadine A ^b,c   Meiser, Bettina ^b,c   Homewood, Judi ^a   Kirk, Judy ^d   Tucker, Kathy ^b,e  

^a MACQUARIE UNIVERSITY   (Australia)

^b PRINCE OF WALES HOSPITAL   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d WESTMEAD HOSPITAL   (Australia)

^e UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ADULT; ARTICLE; AUSTRALIA; BREAST CANCER; CANCER CLASSIFICATION; CANCER RISK; CANCER SCREENING; COLORECTAL CANCER; CONTROLLED STUDY; DECISION SUPPORT SYSTEM; EVIDENCE BASED PRACTICE; FAMILIAL CANCER; FEMALE; GENETIC COUNSELING; GENETIC SCREENING; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; OVARY CANCER; PATIENT ATTITUDE; PATIENT CARE; PATIENT EDUCATION; QUALITATIVE ANALYSIS; RISK MANAGEMENT;

ATTITUDE TO HEALTH; BREAST NEOPLASMS; DECISION SUPPORT SYSTEMS, CLINICAL; FEMALE; GENETIC COUNSELING; GENETIC SCREENING; HUMANS; OVARIAN NEOPLASMS; RISK ASSESSMENT; RISK FACTORS;

EID: 38149035993     PISSN: 10906576     EISSN: None     Source Type: Journal    
DOI: 10.1089/gte.2007.0013     Document Type: Article

References (37)

1. American Society of Clinical Oncology (2003) American Society of Clinical Oncology Policy Statement Update: Genetic Testing for Cancer Susceptibility. J Clin Oncol 21:1-10.
2. Australian Cancer Network (November 1999) Guidelines on familial aspects of cancer. Australian Cancer Network, Sydney.
3. Berth H, Balck F, Dinkel A (2002) Attitudes toward genetic testing in patients at risk for HNPCC/FAP and the German population. Genet Test 6:273-280.
4. Chen S, Iversen ES, Friebel T, Finkelstein D, Weber BL, Eisen A, Peterson LE, et al. (2006) Characterization of BRCA1 and BRCA2 mutations in a large United States sample. J Clin Oncol 24:863-871.
5. Claes E, Denayer L, Evers-Kiebooms G, Boogaerts A, Legius E (2004) Predictive testing for hereditary non-polyposis colorectal cancer: Motivation, illness representations and short-term psychological impact. Patient Educ Couns 55:265-274.
6. Collins V, Halliday J, Warren R, Williamson R (2000) Cancer worries, risk perceptions, and associations with interest in DNA testing and clinic satisfaction in a familial colorectal cancer clinic. Clin Genet 58:460-468.
7. de Jong AE, Hendriks YM, Kleibeuker JH, de Boer SY, Cats A, Griffioen G, Nagengast FM, Nelis FG, Rookus MA, Vasen HF, de Jong AE, Hendriks YMC, Kleibeuker JH, de Boer SY, Cats A, Griffioen G, Nagengast FM, Nelis FG, Rookus MA, Vasen HFA (2006) Decrease in mortality in Lynch syndrome families because of surveillance. Gastroenterology 130:665-671.
8. Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, Bishop DT, et al. (1998) Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet 62:676-689.
9. Gaff C, Collins V, Symes T, Halliday J (2005) Facilitating family communication about predictive testing: Probands' perceptions. J Genet Couns 14:133-140.
10. Glanz K, Grove J, Lerman C, Gotay C, Le Marchand L (1999) Correlates of intentions to obtain genetic counseling and colorectal cancer gene testing among at-risk relatives from three ethnic groups. Cancer Epidemiol Biomarkers Prev 8:329-336.
11. Kausmeyer DT, Lengerich EJ, Kluhsman BC, Morrone D, Harper GR, Baker MJ (2006) A survey of patients' experiences with the cancer genetic counseling process: Recommendations for cancer genetics programs. J Genet Couns 15:409-431.
12. Keller M, Jost R, Haunstetter CM, Kienle P, Knaebel HP, Gebert J, Sutter C, Knebel-Doeberitz M, Cremer F, Mazitschek U, Keller M, Jost R, Haunstetter CM, Kienle P, Knaebel HP, Gebert J, Sutter C, Knebel-Doeberitz Mv, Cremer F, Mazitschek U (2002) Comprehensive genetic counseling for families at risk for HNPCC: impact on distress and perceptions. Genet Test 6:291-302.
13. Kinney AY, Choi YA, DeVellis B, Millikan R, Kobetz E, Sandler RS (2000) Attitudes toward genetic testing in patients with colorectal cancer. Cancer Pract 8:178-186.
14. Lerman C, Hughes C, Trock BJ, Myers RE, Main D, Bonney A, Abbaszadegan MR, Harty AE, Franklin BA, Lynch JF, Lynch HT (1999) Genetic testing in families with hereditary nonpolyposis colon cancer. JAMA 281:1618-1622.
15. Lerman C, Marshall J, Audrain J, Gomez-Caminero A (1996) Genetic testing for colon cancer susceptibility: Anticipated reactions of patients and challenges to providers. Int J Cancer 69:58-61.
16. Levy-Lahad E, Friedman E (2007) Cancer risks among BRCA1 and BRCA2 mutation carriers. Br J Cancer 96:11-15.
17. Lynch HT, Snyder C, Lynch JF, Karatoprakli P, Trowonou A, Metcalfe K, Narod SA, Gong G, Lynch HT, Snyder C, Lynch JF, Karatoprakli P, Trowonou A, Metcalfe K, Narod SA, Gong G (2006) Patient responses to the disclosure of BRCA mutation tests in hereditary breast-ovarian cancer families. Cancer Genet Cytogenet 165:91-97.
18. Meiser B (2005) Psychological impact of genetic testing for cancer susceptibility: An update of the literature. Psychooncology 14:1060-1074.
19. Meiser B, Butow P, Barratt A, Suthers G, Smith M, Colley A, Thompson E, Tucker K (2000) Attitudes to genetic testing for breast cancer susceptibility in women at increased risk of developing hereditary breast cancer. J Med Genet 37:472-476.
20. Meiser B, Butow P, Friedlander M, Barratt A, Schnieden V, Brown J, Tucker K (2002) Psychological impact of genetic testing for women for breast cancer susceptibility. Eur J Cancer 38:2025-2033.
21. Meiser B, Collins V, Warren R, Gaff C, St John DJ, Young MA, Harrop K, Brown J, Halliday J (2004) Psychological impact of genetic testing for hereditary non-polyposis colorectal cancer. Clin Genet 66:502-511.
22. Miles MB, Huberman AM (1994) Qualitative data analysis: An expanded sourcebook. Sage, London
23. Narod S, Gong G (2006) Patient responses to the disclosure of BRCA mutation tests in hereditary breast-ovarian cancer families. Cancer Genet Cytogenet 165:91-97.
24. National Breast Cancer Centre (2000) Current best advice about familial aspects of breast/ovarian cancer. NHMRC National Breast Cancer Centre, Sydney.
25. National Breast Cancer Centre (2006) Magnetic resonance imaging for the early detection of breast cancer in women at high risk: A systematic review of the evidence. Australian Government Department of Health and Ageing, Camperdown, NSW.
26. Pasacreta JV (2003) Psychosocial issues associated with genetic testing for breast and ovarian cancer risk: An integrative review. Cancer Invest 21:588-623.
27. Peters N, Domcheck SM, Rose A, Polis R, Stopfer J, Armstrong K (2005) Knowledge, attitudes, and utilization of BRCA1/2 testing among women with early-onset breast cancer. Genet Test 9:48-53.
28. Quehenberger F, Vasen HFA, Van Houwelingen HC (2005) Risk of colorectal and endometrial cancer for carriers of mutations of the hMLH1 and hMSH2 gene: Correction for ascertainment. J Med Genet 42:491-496.
29. Smith JA, Michie S, Allanson A, Elwy R (2000) Certainty and uncertainty in genetic counselling: A qualitative case study. Psychol Health 15:1-12.
30. SPSS Inc. (2005) Statistical Program for the Social Sciences: Release 14.0. SPSS Inc., Chicago, IL.
31. Strate LL, Syngal S (2005) Hereditary colorectal cancer syndromes. Cancer Causes Control 16:201-213.
32. van Dijk S, Timmermans DRM, Meijers-Heijboer H, Tibben A, van Asperen CJ, Otten W (2006) Clinical characteristics affect the impact of an uninformative DNA test result: The course of worry and distress experienced by women who apply for genetic testing for breast cancer. J Clin Oncol 24:3672-3677.
33. van Roosmalen MS, Stalmeier PF, Verhoef LC, Hoekstra-Weebers JE, Oosterwijk JC, Hoogerbrugge N, Moog U, van Daal WA (2004) Impact of BRCA1/2 testing and disclosure of a positive test result on women affected and unaffected with breast or ovarian cancer. Am J Med Genet A 124:346-355.
34. Wainberg S, Husted J, Wainberg S, Husted J (2004) Utilization of screening and preventive surgery among unaffected carriers of a BRCA1 or BRCA2 gene mutation. Cancer Epidemiol Biomarkers Prev 13:1989-1995.
35. Wakefield CE, Meiser B, Homewood J, Peate M, Kirk J, Warner B, Lobb E, Gaff C, Tucker K (2007) Development and pilot testing of two decision aids for individuals considering genetic testing for cancer risk. J Genet Couns 16:325-339.
36. Wakefield CE, Meiser B, Homewood J, Peate M, Taylor A, Lobb E, Kirk J, Young M, Williams R, Dudding T, Tucker K (in press) A randomized controlled trial of a decision aid for women considering genetic testing for breast and ovarian cancer risk. Breast Cancer Res Treat (in press).
37. Watson M, Foster C, Eeles R, Eccles D, Ashley S, Davidson R, Mackay J, Morrison PJ, Hopwood P, Evans DG, Psychosocial Study C (2004) Psychosocial impact of breast/ovarian (BRCA1/2) cancer-predictive genetic testing in a UK multi-centre clinical cohort. Br J Cancer 91:1787-1794.